Clinical InvestigationParathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism
KEYWORDS
Cited by (0)
HK has received honoraria and/or consulting fees from Bayer Yakuhin and Kyowa Hakko Kirin. MT has received consulting fees from Kyowa Hakko Kirin. KI has received honoraria and/or consulting fees from Astellas Pharma, Bayer Yakuhin, Chugai Pharmaceutical, Daiichi Sankyo, Kyowa Hakko Kirin, Merck Sharp & Dohme Corp., Mochida Pharmaceutical, Teijin Pharma, and Torii Pharmaceutical. YT has received honoraria, consulting fees, and/or grant/research support from Asahi Kasei Medical, Astellas Pharma, Baxter, Bayer Yakuhin, Chugai Pharmaceutical, Fuso Pharmaceutical Industries, GlaxoSmithKline K.K., Kissei Pharmaceutical, Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Otsuka Pharmaceutical, Shionogi Pharmaceutical, Taisho Pharmaceutical, Takeda Pharmaceutical, Teijin Pharma, and Torii Pharmaceutical. MF has received honoraria, consulting fees, and/or grant/research support from Astellas Pharma, Bayer Yakuhin, Kyowa Hakko Kirin, Ono Pharmaceutical, and Torii Pharmaceutical. AW declared no competing interests.